Evidence map›Paper›PMID 37175318›Full record

ArticleMolecules (Basel, Switzerland)2023

Different In Silico Approaches Using Heterocyclic Derivatives against the Binding between Different Lineages of SARS-CoV-2 and ACE2.

Federica Sipala, Gianfranco Cavallaro, Giuseppe Forte, Cristina Satriano, Alessandro Giuffrida, Aurore Fraix, Angelo Spadaro, Salvatore Petralia, Carmela Bonaccorso, Cosimo Gianluca Fortuna and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Federica SipalaDepartment of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.ORCID 0000-0002-8477-3419
Gianfranco CavallaroDepartment of Chemical Science, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.ORCID 0009-0009-6759-3860
Giuseppe ForteDepartment of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.
Cristina SatrianoDepartment of Chemical Science, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.ORCID 0000-0001-5348-5863
Alessandro GiuffridaDepartment of Chemical Science, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.ORCID 0000-0003-3497-2759
Aurore FraixDepartment of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.ORCID 0000-0002-8328-3290
Angelo SpadaroDepartment of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.
Salvatore PetraliaDepartment of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.ORCID 0000-0001-5692-1130
Carmela BonaccorsoDepartment of Chemical Science, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.ORCID 0000-0001-9112-5623
Cosimo Gianluca FortunaDepartment of Chemical Science, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.ORCID 0000-0003-1889-886X
Simone RonsisvalleDepartment of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy.ORCID 0000-0003-3488-7343
University of Catania · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over the last few years, the study of the SARS-CoV-2 spike protein and its mutations has become essential in understanding how it interacts with human host receptors. Since the crystallized structure of the spike protein bound to the angiotensin-converting enzyme 2 (ACE2) receptor was released (PDB code 6M0J), in silico studies have been performed to understand the interactions between these two proteins. Specifically, in this study, heterocyclic compounds with different chemical characteristics were examined to highlight the possibility of interaction with the spike protein and the disruption of the interaction between ACE2 and the spike protein. Our results showed that these compounds interacted with the spike protein and interposed in the interaction zone with ACE2. Although further studies are needed, this work points to these heterocyclic push-pull compounds as possible agents capable of interacting with the spike protein, with the potential for the inhibition of spike protein-ACE2 binding.

Indexed as

COVID-19SARS-CoV-2Angiotensin-Converting Enzyme 2HumansProtein BindingSpike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2Spike Glycoprotein, Coronavirusspike protein, SARS-CoV-2heterocyclic derivativesmolecular modelingSARS-CoV-2

Identifiers

PMID37175318
PMCPMC10180195
OpenAlexW4376630421

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.